ifinatamab deruxtecan

Ifinatamab deruxtecan is an investigational, potential first-in-class antibody-drug conjugate (ADC) specifically engineered to target B7-H3 (CD276), a transmembrane immunoregulatory protein highly expressed in various solid tumors. The drug consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked via a tetrapeptide-based cleavable linker to multiple molecules of DXd, a topoisomerase I inhibitor payload derived from exatecan. This design enables targeted delivery of the cytotoxic agent directly to tumor cells expressing B7-H3, aiming for enhanced antitumor activity with reduced systemic toxicity. Ifinatamab deruxtecan was discovered by Daiichi Sankyo and is being jointly developed with Merck. It is currently under clinical investigation for several advanced or metastatic solid tumors including small cell lung cancer (SCLC), esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), prostate cancer, and other malignancies[1][4][6][10].

Other names

anti-B7-H3/DXd ADCanti-B7H3/DXd antibody-drug conjugate